AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19151302
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine with 2% lidocaine (100 mg + 400 mg)
Trial: 19151302
Drug: 0.75% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% ropivacaine (300 mg)
Trial: 19151302
Drug: 0.75% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% ropivacaine with 2% lidocaine (150 mg + 400 mg)
Trial: 25130281
Drug: Mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg once daily
Trial: 25440809
Drug: Rosuvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (40 mg on admission followed by 20 mg/d; statin group, n = 252)
Trial: 20168272
Drug: Modified Early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Early Treatment Diabetic Retinopathy Study laser photocoagulation
Trial: 2198075
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (VCMP/VBAP)
Trial: 6638418
Drug: Endobronchial double
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endobronchial double lumen tube for one-lung ventilation with intravenous anaesthesia and muscular relaxation
Trial: 23873901
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with intravitreal ranibizumab and topical ketorolac (group 1)
Trial: 19787290
Drug: pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pioglitazone (30 mg)
Trial: 19787290
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard therapy (control)
Trial: 15370932
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/d) + Relapse Prevention therapy
Trial: 15370932
Drug: Naltrexone (placebo)
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone (placebo) + Drug Counseling
Trial: 11092518
Drug: Soy breakfast
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy breakfast cereal (providing 36 g/d soy protein and 168 mg/d isoflavones)
Trial: 3082694
Drug: Flunisolide nasal
RxNorm normalized name: flunisolide nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunisolide nasal spray plus terfenadine tablets (50 mcg flunisolide to each nostril twice daily and 60 mg terfenadine twice daily)
Trial: 3082694
Drug: Terfenadine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine alone (60 mg terfenadine twice daily)
Trial: 3272745
Drug: Bupivacaine (0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (0.25% epidural, 6 to 12 ml/hour)
Trial: 3272745
Drug: Morphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.1 mg/kg intramuscularly, no more frequently than every 4 hours)
Trial: 20506391
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg, 2 subcutaneous injections at 7-day intervals)
Trial: 18402744
Drug: KS palm
RxNorm normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KS palm grip (26173 ML)
Trial: 9059137
Drug: Prednisolone at
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone at 2.00 am (5 or 7.5 mg daily)
Trial: 2874527
Drug: Cysteamine (somatostatin-depleting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteamine (somatostatin-depleting agent) at maximum tolerated dosage for 2 weeks
Trial: 29982534
Drug: Fructans (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructans (6 g/d)
Trial: 15804155
Drug: Increased flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased flow through the CDI sensor to approximately 400 mL/min
Trial: 12424162
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (20 mg per day for 14 days)
Trial: 9054781
Drug: Assertive community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertive community treatment alone
Trial: 9090733
Drug: Assertive community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertive community treatment with community workers
Trial: 10899490
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined HRT (ccHRT) containing estradiol (2 mg/d) + estriol (1 mg/d) + norethindrone acetate (1 mg/d)
Trial: 9035017
Drug: Etodolac 200
RxNorm normalized name: etodolac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 200 mg qid
Trial: 7705193
Drug: Washout period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Washout period (2 months after discontinuation of Goshajinkigan)
Trial: 3588662
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg bromocriptine
Trial: 16478755
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg bromocriptine
Trial: 3588662
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg bromocriptine
Trial: 21330907
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No gel
Trial: 25935783
Drug: TrimoSan gel
RxNorm normalized name: Triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TrimoSan gel
Trial: 23370697
Drug: Inhalation during
RxNorm normalized name: Pro-C-Dure 6 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation during the lift
Trial: 18071341
Drug: Hypocaloric diet
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric diet plus sibutramine (10 mg per day)
Trial: 16863011
Drug: Single-dose sertaconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose sertaconazole vaginal tablet (500 mg)
Trial: 16863011
Drug: Conventional 3-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional 3-dose econazole vaginal tablet (150 mg)
Trial: 10673309
Drug: Interferon-alpha 2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 2b plus 200 mg ketoprofen twice a day
Trial: 2719462
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg of ciprofloxacin twice daily for 5 days
Trial: 2719462
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg of ciprofloxacin twice daily plus 300 mg of rifampin twice daily for 21 days
Trial: 141237
Drug: alcuroium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alcuroium 0.3 mg/kg
Trial: 141237
Drug: gallamine 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gallamine 1.8 mg/kg
Trial: 141237
Drug: suxamethonium 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium 0.8 mg/kg
Trial: 31279278
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage (1g/100ml curry) - single meal or multiple meals
Trial: 28355706
Drug: Rock salt
RxNorm normalized name: Nivea Men Rock Salts Body Wash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rock salt aerosol therapy
Trial: 12464165
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment (control group)
Trial: 25091666
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of Rotarix vaccine (n=45)
Trial: 19411529
Drug: Survey respondents
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Survey respondents comparing oral health to arthritis
Trial: 11810416
Drug: Oral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estrogen plus progestogen (E‐P)
Trial: 9180950
Drug: 8OU of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8OU of BoTox injected in four quadrants (1 ml in each quadrant‐20 U/ml) (n = 8)
Trial: 9180950
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution as placebo injected in the same way (n = 5)
Trial: 1827020
Drug: Isradipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (5 mg twice daily)
Trial: 31521613
Drug: CHMI-derived parasites
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHMI-derived parasites from volunteer groups receiving different PfSPZ dose and route
Trial: 10929273
Drug: Olanzapine 5
RxNorm normalized name: olanzapine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 5 mg daily
Trial: 10929273
Drug: Low-dose pimozide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose pimozide 2 mg daily
Trial: 10929273
Drug: Low-dose pimozide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose pimozide 4 mg daily
Trial: 6465511
Drug: Urapidil (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil (0.6 mg/kg before induction, 0.4 mg/kg +/- 0.2 mg/kg before termination)
Trial: 25208756
Drug: Albiglutide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albiglutide (30 mg once a week, n=504)
Trial: 25208756
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (10 U once a day, n=241)
Trial: 1662796
Drug: M37 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M37 vaccine 10(4) PFU
Trial: 4031977
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy without BCNU
Trial: 23762354
Drug: Gastric irrigation
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric irrigation with 2 L saline solution before ESD
Trial: 23762354
Drug: Gastric irrigation
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric irrigation with saline solution
Trial: 19115593
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml of HES 130/0.4 (Gr II : n = 61)
Trial: 14562117
Drug: chemotherapy (hydroxyurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy (hydroxyurea (HU))
Trial: 14562117
Drug: chemotherapy (busulfan)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy (busulfan)
Trial: 25457928
Drug: Telephone cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone cognitive-behavioral therapy (TCBT)
Trial: 12412822
Drug: Zolmitriptan nasal
RxNorm normalized name: Zolmitriptan Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan nasal spray (2.5, 5.0, or 10 mg)
Trial: 17883519
Drug: Zolmitriptan (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan (all formulations)
Trial: 12412822
Drug: Zolmitriptan nasal
RxNorm normalized name: Zolmitriptan Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan nasal spray vs oral formulations
Trial: 2225364
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of adenosine (80 micrograms/min or more)
Trial: 2225364
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of adenosine (140 micrograms/kg/min)
Trial: 2225364
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of adenosine (up to 240 micrograms/min)
Trial: 25833163
Drug: Hib-MenAC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib-MenAC vaccine
Trial: 28277801
Drug: Licensed Hib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed Hib vaccine and MenAC vaccine
Trial: 12701671
Drug: alprazolam with
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: alprazolam with pre-treatment of carbamazepine
Trial: 10720509
Drug: Recombinant gp120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant gp120 vaccines (various doses from SF‐2 or MN strains)
Trial: 10720509
Drug: Accelerated immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated immunization schedule with lowest dose of SF‐2 vaccine
Trial: 8240640
Drug: Flumazenil (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.2 mg initial injection, followed by 0.1 mg per minute until desired vigilance)
Trial: 27354081
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin given from 11 to 13 weeks' gestation
Trial: 23980355
Drug: Routine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine therapy
Trial: 28983705
Drug: Quarterly intravenous
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quarterly intravenous bisphosphonates (3 mg ibandronate every 3 months)
Trial: 28983705
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral bisphosphonates (70 mg alendronate orally once each week for 12 months)
Trial: 28983705
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral bisphosphonates (70 mg alendronate)
Trial: 23782588
Drug: Tocilizumab 162
RxNorm normalized name: TOCILIZUMAB 162MG/0.9ML AUTOINJECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 162 mg subcutaneously QW
Trial: 16773938
Drug: Immediate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate therapy for patients with moderate or high conversion risk (e.g. elderly age, greater intraocular pressure, central corneal thickness, greater cup/disc ratio)
Trial: 8667057
Drug: CCK‐8 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCK‐8 infusion (0.3 ng/kg per min for 60 min)
Trial: 8667057
Drug: CCK‐8 bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCK‐8 bolus injection (0.04 microgram/kg)
Trial: 1539732
Drug: CCK‐8 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCK‐8 infusion
Trial: 8667057
Drug: CCK‐8 bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCK‐8 bolus injection
Trial: 8150549
Drug: Cefpirome 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome 0.5 g
Trial: 1601759
Drug: Cefpirome 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome 1.0 g every 12 h for 3.5 days
Trial: 1601759
Drug: Cefpirome (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome (all doses)
Trial: 9683366
Drug: Simultaneous radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous radiation and chemotherapy (cis-DDP, 5-fluorouracil, leucovorin)
Trial: 30901867
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg ondansetron
Trial: 25293524
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg droperidol
Trial: 2256469
Drug: Ciclosporin (CS)
RxNorm normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ciclosporin (CS) at low doses (not exceeding 5 mg/kg/day)
Trial: 19017589
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement therapy
Trial: 21392068
Drug: Combined motivational
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined motivational enhancement and cognitive behaviour therapy
Trial: 20307457
Drug: Steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid injection to heel
Trial: 11512649
Drug: Alfentanil 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 10 microg x kg(‐1) and suxamethonium 1 mg x kg(‐1)
Trial: 17823012
Drug: Periarticular injections
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular injections
Trial: 15183925
Drug: Caffeine and
RxNorm normalized name: caffeine and sodium benzoate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine and glucose drink (68 g carbohydrate and 38 mg caffeine)
Trial: 15183925
Drug: Caffeine and
RxNorm normalized name: caffeine and sodium benzoate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine and glucose drink (68 g carbohydrate and 46 mg caffeine)
Trial: 31116468
Drug: Various treatments/interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments/interventions in physiological research studies
Trial: 26001567
Drug: Rivastigmine 0mg
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine 0mg twice a day
Trial: 26001567
Drug: Rivastigmine 1.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine 1.5mg twice a day
Trial: 26001567
Drug: Rivastigmine 3mg
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine 3mg twice a day
Trial: 15315849
Drug: Duplex vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duplex vaccine
Trial: 15315849
Drug: diTeBooster vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diTeBooster vaccine
Trial: 9311648
Drug: Artesunate suppositories
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate suppositories (200 mg/capsule) given rectally at 0, 4, 8, 12, 24, 36, 48, and 60 hr (total = 1,600 mg) followed by oral mefloquine (750 mg at 72 hr and 500 mg at 84 hr)
Trial: 9311648
Drug: Artesunate suppositories
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate suppositories (200 mg/capsule) given rectally at 0, 12, 24, 36, 48, and 60 hr (total = 1,200 mg) followed by oral mefloquine (750 mg at 72 hr and 500 mg at 84 hr)
Trial: 8110401
Drug: Rice-based solution
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice-based solution without electrolytes (Group A)
Trial: 8110401
Drug: Rice-based solution
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice-based solution with electrolytes (Group B)
Trial: 2437278
Drug: High-dose gammaglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose gammaglobulin 400 mg/kg/d for 3 days plus aspirin 30 mg/kg/d
Trial: 2437278
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone at the same dosage (30 mg/kg/d)
Trial: 25636858
Drug: Target Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target Inhalation Mode (TIM)
Trial: 26669827
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 77 mg of A1-PI
Trial: 791333
Drug: Labetalol 1.0‐2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 1.0‐2.0 mg/kg intravenously
Trial: 6519163
Drug: Propranolol 10
RxNorm normalized name: propranolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 10 mg intravenously
Trial: 30952158
Drug: Chloroquine (25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (25mg base/kg) plus primaquine (1 mg/kg/day for 7 days)
Trial: 30952158
Drug: Dihydroartemisinin-piperaquine (dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (dihydroartemisinin 7mg/kg and piperaquine 55mg/kg) plus primaquine (0.5 mg/kg/day for 14 days)
Trial: 30952158
Drug: 14-day high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day high-dose primaquine regimen
Trial: 30952158
Drug: 7-day high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day high-dose primaquine regimen
Trial: 28938439
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg metformin with cholecystokinin (0.4 pmol × kg‐1 × min‐1)
Trial: 28938439
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg metformin without cholecystokinin
Trial: 22404879
Drug: Mindfulness-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based therapy (MBT) consisting of eight 1-hour sessions over 4 weeks
Trial: 17442602
Drug: Intravenous adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous adenosine (10mg)
Trial: 15007518
Drug: Cognitive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive group therapy